USPTO Art Unit 1626 Prosecution Statistics

Art Unit Information

Art Unit: 1626
Group: 1620
Tech Center: 1600
Total Cases: 27,480
Last Active: March 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19072385POLQ INHIBITORSMarch 2025April 2025Allow200YesNo
19063141NOVEL COMPOUNDSFebruary 2025May 2025Allow200YesNo
19042986MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASESJanuary 2025April 2025Allow300YesNo
19020776CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTATJanuary 2025March 2025Allow200YesNo
19003381ORGANOSELENIUM BENZIMIDAZOLE COMPOUNDS FOR TREATING CANCERDecember 2024March 2025Allow200NoNo
19002491CompoundsDecember 2024May 2025Allow400YesNo
19001374Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient OpeningDecember 2024April 2025Allow300YesNo
18973849LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATIONDecember 2024March 2025Allow300NoNo
18968441MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSIONDecember 2024March 2025Allow311NoNo
18868756C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCERNovember 2024April 2025Allow510YesNo
18865727N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGSNovember 2024April 2025Allow500NoNo
18939592CYTOTOXIC TREATMENT OF CANCER CELLSNovember 2024January 2025Allow210NoNo
18904487ROCAGLATE DERIVATIVES AND USES THEREOFOctober 2024February 2025Allow500YesNo
18883472APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASESSeptember 2024November 2024Allow200NoNo
18843302TRIAZOLYL CROSS-LINKING AGENT AS WELL AS PREPARATION METHOD AND USE THEREOFSeptember 2024April 2025Allow801YesNo
18800581NK3 MODULATORS AND USES THEREOFAugust 2024November 2024Allow300YesNo
18799676METHOD FOR CONTACTING CANCER CELLS WITH ANTITUMOR AGENT AND APOPTOTIC INDUCERAugust 2024October 2024Allow210NoNo
18780132Aminopyrimidine Derivatives as Cyclin-Dependent Kinase InhibitorsJuly 2024January 2025Allow600YesNo
18768367BENZOPYRIMIDINE COMPOUNDS AND USE THEREOFJuly 2024January 2025Allow710YesNo
18767494PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USEJuly 2024December 2024Allow510YesNo
18764298BIO-BASED EPOXY CHAIN EXTENDER AND PREPARATION METHOD THEREOFJuly 2024January 2025Allow720NoNo
18764274LASOFOXIFENE TREATMENT OF BREAST CANCERJuly 2024May 2025Allow1010YesNo
18763262SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAMEJuly 2024February 2025Allow800YesNo
18745664PARP INHIBITORS FOR TREATING CANCER AND ASTHMAJune 2024April 2025Allow1010YesNo
18743634HETEROARYL AZOLE COMPOUND AND PEST CONTROL AGENTJune 2024February 2025Allow800NoNo
18742840CRYSTALLINE FORMS OF COMPOSITIONS COMPRISING PSILOCIN AND PSILOCYBINJune 2024June 2025Allow1210NoNo
18741888Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor ModulatorsJune 2024December 2024Allow610NoNo
18718991COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCERJune 2024March 2025Allow910YesNo
18717094PSILOCYBIN DERIVATIVESJune 2024April 2025Allow1010NoNo
18679720FORMS OF ATICAPRANTMay 2024August 2024Allow200YesNo
18680473METHODS OF TREATING MOOD DISORDERSMay 2024December 2024Allow610NoNo
18731154CFTR REGULATORS AND METHODS OF USE THEREOFMay 2024April 2025Allow1000NoNo
18678114PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSMay 2024March 2025Allow920NoNo
18714111CONJUGATES, THEIR COMPOSITIONS, AND THEIR RELATED METHODSMay 2024April 2025Allow1100YesNo
18672808PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORSMay 2024May 2025Allow1201YesNo
18671182PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORSMay 2024December 2024Allow600NoNo
18666109SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINEMay 2024March 2025Allow1000YesNo
18662345Crystalline Forms Of An Androgen Receptor ModulatorMay 2024June 2025Abandon1310NoNo
186613373-(2-(1,3-DIOXOISOINDOLIN-2-YL)ETHYL)-5-(2-HYDROXY-5-NITROBENZYLIDENE)THIAZOLIDINE-2,4-DIONE AS A POTENTIAL ANTITUMOR AND APOPTOTIC INDUCERMay 2024July 2024Allow200NoNo
18657122SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORSMay 2024July 2025Allow1410NoNo
186502073-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOFApril 2024July 2024Allow300YesNo
18638989HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38April 2024April 2025Allow1210YesNo
18637425Salts of Obicetrapib and Processes for their Manufacture and Intermediates ThereofApril 2024May 2025Allow1300YesNo
18636763PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUNDApril 2024July 2024Allow320YesNo
186369053-(3-(1,3-DIOXOISOINDOLIN-2-YL) PROPYL)-5-(4-FLUOROBENZYLIDENE) THIAZOLIDINE-2,4-DIONE AS A POTENTIAL ANTITUMOR AND APOPTOTIC INDUCERApril 2024July 2024Allow300NoNo
18636634Prodigiosin Analogs And Methods Of UseApril 2024February 2025Allow1010YesNo
18631374PYRIMIDO[1',6':1,5]PYRAZOLO[4,3-C][2,7]NAPHTHYRIDINES AS CK2 INHIBITORSApril 2024December 2024Allow811NoNo
18629313BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORSApril 2024May 2025Allow1320YesNo
18628560PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITORApril 2024January 2025Allow900YesNo
18624982POLYMORPHIC COMPOUNDS AND USES THEREOFApril 2024March 2025Allow1210NoNo
18621997SILICON CONTAINING DETECTABLE COMPOUNDS AND USES THEREOFMarch 2024February 2025Allow1110NoNo
18621972POLYMORPH FORM OF PITOLISANT HYDROCHLORIDEMarch 2024September 2024Allow610NoNo
18622657PROCESSES FOR PREPARING SOLID STATE FORMSMarch 2024March 2025Allow1121NoNo
18604747ORGANIC COMPOUND SALTSMarch 2024May 2024Allow200YesNo
18605379THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOFMarch 2024March 2025Allow1201YesNo
18600018DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USEMarch 2024March 2025Allow1210NoNo
18597990CRYSTALLINE FORMS OF A NEUROACTIVE STEROIDMarch 2024June 2024Allow300NoNo
18597119Preparation method of glufosinate or derivatives thereofMarch 2024April 2025Allow1440YesYes
18593842INJECTABLE PHOTOTHERMAL HYDROGEL BASED ON MELANIN, PREPARATION METHOD, AND APPLICATION THEREOFMarch 2024June 2024Allow401NoNo
18591753NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORSFebruary 2024September 2024Allow710YesNo
18591965HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORSFebruary 2024March 2025Abandon1320NoNo
18589841HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDERFebruary 2024May 2024Allow200YesNo
18590133THIAZOLE TETHERED ORGANOSELENIDES AS 5-LIPOXYGENASE INHIBITORSFebruary 2024April 2024Allow200NoNo
18588051HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORSFebruary 2024March 2025Abandon1310NoNo
18444450ANALOGS OF XANOMELINEFebruary 2024June 2024Allow420NoNo
18443959COMPOUND OR SALT THEREOF AND LIPID PARTICLESFebruary 2024March 2025Allow1300YesNo
18442885CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOFFebruary 2024February 2025Allow1210NoNo
18440166SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOFFebruary 2024April 2025Allow1421YesNo
18438838TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAMEFebruary 2024March 2025Allow1310NoNo
18437502QUINOLINE COMPOUNDS AS INHIBITORS OF KRASFebruary 2024March 2025Allow1301NoNo
18436024OX2R CompoundsFebruary 2024April 2025Abandon1401NoNo
18435082SOLID DOSAGE FORM HAVING EXCELLENT STABILITYFebruary 2024June 2025Allow1610NoNo
18434560Cyclic Thiol ProdrugsFebruary 2024May 2025Abandon1501NoNo
18681394COLCHICINE SOLUTIONFebruary 2024September 2024Allow710NoNo
18432824METHODS AND MATERIALS FOR IMPROVING ARTERIOVENOUS FISTULA MATURATION AND MAINTAINING ARTERIOVENOUS FISTULA FUNCTIONALITYFebruary 2024October 2024Allow900YesNo
184318984-CHLORO-N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024April 2024Allow300NoNo
184287974-CHLORO-N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024April 2024Allow200YesNo
184254484-CYANO-1-(2-OXO-2-(SUBSTITUTED PHENYL) ETHYL) PYRIDIN-1-IUM BROMIDES AS ANTI-TUBERCULAR AGENTSJanuary 2024September 2024Allow810YesNo
18426035NITRIC OXIDE RELEASING PRODRUGS OF MDA AND MDMAJanuary 2024June 2025Allow1710YesNo
18422118TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIAJanuary 2024March 2025Allow1410NoNo
18422175INDOLOCARBAZOLE ANALOGS OF STAUROSPORINE AND METHODS OF SYNTHESIS THEREOFJanuary 2024August 2024Allow700YesNo
18422793PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOFJanuary 2024May 2025Abandon1610NoNo
18420446FUSED RING COMPOUND HAVING UREA STRUCTUREJanuary 2024November 2024Allow1010NoNo
18418560ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERSJanuary 2024October 2024Allow800NoNo
184179001-(NAPHTHALEN-2-YLOXY)-3-(PIPERIDIN-1-YL)PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024August 2024Abandon701NoNo
18415359FLUORO BETA-CARBOLINE COMPOUNDSJanuary 2024April 2025Allow1501YesNo
18414958CRYSTAL FORMS OF IMMUNOMODULATORSJanuary 2024November 2024Allow1010YesNo
18414019SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOFJanuary 2024August 2024Allow710YesNo
18413842ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOFJanuary 2024January 2025Allow1221YesNo
18407400SHP2 INHIBITOR AND USE THEREOFJanuary 2024March 2024Allow200YesNo
18402325CROWN ETHER CARBENES AND METHODS OF USEJanuary 2024January 2025Allow1310NoNo
18401918POLYELECTROCHROMISM OF ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED TWO Ru(CO)Cl(PiPr3)2 ENTITIESJanuary 2024March 2024Allow200NoNo
18402493BIPYRAZOLE DERIVATIVES AS JAK INHIBITORSJanuary 2024November 2024Allow1010NoNo
183959923-(4-CHLOROPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}- 1,2,4-OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDDecember 2023April 2024Allow400NoNo
183962433-(4-CHLOROPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}- 1,2,4-OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDDecember 2023March 2024Allow200NoNo
18395348EP2 ANTAGONIST COMPOUNDSDecember 2023November 2024Allow1111NoNo
18395130PYRAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AS CK2 INHIBITORSDecember 2023March 2024Allow300YesNo
18394624COMPOUNDSDecember 2023March 2025Abandon1501NoNo
18393813METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOFDecember 2023February 2024Allow200NoNo
18392680FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASEDecember 2023April 2025Allow1610YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1626.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
76
Examiner Affirmed
47
(61.8%)
Examiner Reversed
29
(38.2%)
Reversal Percentile
74.8%
Higher than average

What This Means

With a 38.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
784
Allowed After Appeal Filing
276
(35.2%)
Not Allowed After Appeal Filing
508
(64.8%)
Filing Benefit Percentile
61.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 35.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1626 - Prosecution Statistics Summary

Executive Summary

Art Unit 1626 is part of Group 1620 in Technology Center 1600. This art unit has examined 27,480 patent applications in our dataset, with an overall allowance rate of 75.3%. Applications typically reach final disposition in approximately 22 months.

Comparative Analysis

Art Unit 1626's allowance rate of 75.3% places it in the 42% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1626 receive an average of 1.21 office actions before reaching final disposition (in the 9% percentile). The median prosecution time is 22 months (in the 87% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.